• Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KOTRA
    • KTO
    • MSS
    • NIPA
    • SBA
    • SFL
  • Programs
    • SGSC Global Bootcamp 2021
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
    • SFL Global Program
    • KTO Global Showcase
  • Investment Opportunities
    • SGSC Demo Day
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • register
  • login
KoreaTechDesk
No Result
View All Result
KoreaTechDesk
No Result
View All Result
Home Health & Bio

Korean pharmaceutical startup HuMab heralds a new era of genome engineering

Jeon Jinju by Jeon Jinju
January 22, 2020
in Health & Bio
7
Korean pharmaceutical startup HuMab heralds a new era of genome engineering
11
SHARES
528
VIEWS
Share on FacebookShare on Twitter

Genome engineering, a type of genetic engineering, is becoming a popular solution to many challenges facing humankind, such as health issues, food shortages, and environmental pollution. Korean pharmaceutical startup HuMab, founded in 2018, wants to contribute to the promotion of human health and well-being through genome engineering technology.

HuMub applies AiCE™(Artificial inter-species Chromosome segment Exchange), more effective technology for genomic engineering than conventional restriction enzyme-based recombinant DNA technology. The company undertakes large-scale and extensive genome engineering tasks on a chromosome level by utilizing a diverse array of programmable nucleases (crispr, talen, zfn, etc.) and microcell-mediated chromosome transfer (MMCT) technologies. These technological advantages of HuMab over other genetic engineering companies have taken genome engineering to another level.

HuMab’s Synthese is a next-generation antibody-drug

The company strives to innovate biotechnology that can contribute to human health and well-being and produce new drugs based on that innovation. Using genomic engineering technology, HuMab is developing SynThese™, the next-generation transgenic mouse platform for the production of fully human monoclonal antibodies. SynThese™ will be the most powerful and flexible transgenic mouse platform to produce therapeutic fully human monoclonal antibodies.

Leveraging the SynThese™ platform, HuMab will enter the new fully human monoclonal antibody-drug market through clinical collaboration with a global pharmaceutical company.  HuMab plans to develop four new antibody drugs in the field of cancer immunotherapy and immune disorder treatments, using SynThese.

AiCE technology provides innovative solutions and products

HuMab uses AiCE™ technology to enable extensive, extensive genome engineering at the chromosome level. Unlike other traditional genetic engineering companies, HuMab’s AiCE™ technology can be extended to genome engineering levels, enabling applications that were not possible with traditional technologies. HuMab is applying its proprietary technology, AiCE™, to not only immunoglobulin genes but other large-scale genes that have not been easily handled so far. The company is looking for partners to develop new fully human monoclonal antibody drugs on the SynThese™ platform and who want to develop innovative products with ideas using AiCE™.

Strong foundation and global outreach plans

HuMab’s CEO, Dr. Oh, received his Ph.D. in molecular genetics and genomics from the University of Goettingen, Germany, in 2000. Over the next 15 years, he garnered extensive experience in R&D and business development in various biotechnology fields as Director of Macrogen and Green Cross Pharmaceuticals and as CEO of ToolGen and ForHumanTech. In 2018, Dr. Oh founded his second startup, HuMab.

At HuMab, Dr. Oh is committed to developing and commercializing the Transgenic Mouse Platform (SynTheseTM), one of the biggest market potentials in the rapidly growing genome engineering field with the newly developed CRISPR technology.

HuMab operates a business model, under which it generates income by licensing-out its original antibody platform technology to global pharmaceuticals and jointly developing new antibody drugs. The company aims to prove the competitiveness of HuMab’s platform technology in the market by finding excellent antibody drug candidates and running pre-clinical trials to secure patent rights of the new drug substance. The company plans to run at least 4 R&D projects and secure IP and resources required for developing and operating clinical trials with global pharmaceutical companies.

HuMab is working hand-in-hand with Korean university hospitals and several world-class life science researchers to achieve its mission of completing the next-generation transgenic mouse platform development by 2020.

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: BiotechnologyGenome EngineeringHealth careHuMabKorean Startup
Previous Post

Korean startup InHandPlus’ smartwatch makes medication adherence easier 

Next Post

Korean startup Sleek Corporation all set to transform and revolutionize the Asian fitness market

Next Post
Korean startup Sleek Corporation all set to transform and revolutionize the Asian fitness market

Korean startup Sleek Corporation all set to transform and revolutionize the Asian fitness market

0 0 votes
Article Rating
Subscribe
Login
Notify of
Please login to comment
7 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
trackback
lire la suite
3 months ago

… [Trackback]

[…] Info to that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
เงินด่วนออนไลน์
3 months ago

… [Trackback]

[…] There you can find 1955 additional Information to that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
maxbet
2 months ago

… [Trackback]

[…] Read More on that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
mushroom dispensary online growing
2 months ago

… [Trackback]

[…] Read More here to that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
sbobet
24 days ago

… [Trackback]

[…] Find More on that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
otherwise
8 days ago

… [Trackback]

[…] Read More here on that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
trackback
quaker chewy bars
2 days ago

… [Trackback]

[…] Read More Info here on that Topic: koreatechdesk.com/korean-pharmaceutical-startup-humab-heralds-a-new-era-of-genome-engineering/ […]

0
No Result
View All Result

Follow Us

FREE NEWSLETTER

Ecosystem Partners




PRODUCTS

Most Popular

  • 10 K-Dramas to watch for some ‘money matters’

    0 shares
    Share 0 Tweet 0
  • Top Korean Dating apps that can help you make new connections in South Korea

    1 shares
    Share 0 Tweet 0
  • Korean startups to showcase technological proficiency at CES 2023 from January 5 to 8 in Las Vegas 

    0 shares
    Share 0 Tweet 0
  • Three Restaurant Apps to try out for a fine dining experience in South Korea  

    9 shares
    Share 9 Tweet 0
  • Korean webtoon ‘Lookism’ creator ‘The Grim Entertainment’ attracts $9.1 million investment

    0 shares
    Share 0 Tweet 0
  • Seoul Robotics aims for an IPO in 2025, post-Series B funding of $ 25 million

    0 shares
    Share 0 Tweet 0
  • Korean electric vehicle charging solutions startup EVAR awarded ‘Triple-Crown’ in CES 2023

    0 shares
    Share 0 Tweet 0
  • Korean startups creating the K-Beauty buzz worldwide

    11 shares
    Share 11 Tweet 0
  • Korean hospitality tech startup Onda attracts over $9 million in investment

    0 shares
    Share 0 Tweet 0
  • Korean startup Accelerator & Venture Capital Fund 1Billion Partners continues investing in promising startups despite ‘cold investment season’

    0 shares
    Share 0 Tweet 0
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter

Copyright © 2023 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • FinTech
    • Gadgets & Electronics
    • Health & Bio
    • IoT
    • Marketplaces & E-commerce
    • Robotics
    • Transportation & Logistics
    • Investments
    • Ecosystem & Lists
  • Interviews
  • Events
    • ComeUp
    • NextRise
  • Governments
    • KISA
    • KISED
    • KOCCA
    • KTO
    • KOTRA
    • MSS
    • NIPA
    • SBA
    • SFL
  • Programs
    • LAUNCHPAD
    • COMEUP STARS 120
    • K-Startup Grand Challenge
    • TIPS X beSUCCESS Global Project
    • SFL Global Program
    • KTO Global Showcase
  • Investment Opportunities
    • Launchpad France Demoday
    • TIPS Global Demoday
    • Launchpad USA Demoday
    • Launchpad Indonesia Demoday
  • Submit an Article
  • Forums
  • register
  • login

Copyright © 2023 KoreaTechDesk | About Us | Sponsorships| Terms of Use |Privacy Policy |Cookie Policy Contact: [email protected] DMCA.com Protection Status

wpDiscuz
7
0
Would love your thoughts, please comment.x
()
x
| Reply

We hope you enjoy our content, May you please give us Feedback regarding our website!

Single Post Feedback

dgdfgfdgdf

What you think about Koreatechdesk, Share your idea with us!

feedback popup

Invitation submission has been closed

Insert/edit link

Enter the destination URL

Or link to existing content

    No search term specified. Showing recent items. Search or use up and down arrow keys to select an item.